Abstract
Multiple myeloma (MM) measurable residual disease (MRD) persisting after treatment is an adverse prognostic factor for progression free survival (PFS) and overall survival.1Genomic mutations occurred in the remaining clonal aberrant plasma cells (A-PCs) are linked to the development of drug resistance and disease relapse.2 Thus, personalised treatment based on the genomic profile of MRD could be highly beneficial and ultimately increase patients’ survival. However, while large-scale sequencing studies have characterised the genome of many malignancies including MM,3–8 the genomic mutations present in MM MRD are at the beginning of investigation.9 Here, we set up an exome sequencing analysis to identify genomic mutations characteristic for MM MRD and explore if they could mediate drug response, resistance or disease progression.
Original language | English |
---|---|
Number of pages | 9 |
Journal | Blood Advances |
Early online date | 9 Sept 2021 |
DOIs | |
Publication status | E-pub ahead of print - 9 Sept 2021 |
Keywords / Materials (for Non-textual outputs)
- multiple myeloma
- mutation
- precision medicine
- residual tumor